一、临床药理学与治疗学 (2024年第115卷第6期)

June 2024 - Volume 115 - Issue 6 (2024年6月第115卷第6期)
https://ascpt.onlinelibrary.wiley.com/toc/15326535/2024/115/6

Perspective（观点）
1. 针对囊性纤维化的Elexacaftor/Tezacaftor/Ivacaftor的药物动力学增强：一种降低成本以解决全球获取差异的策略
Pharmacokinetic Enhancement of Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis: A Cost Reduction Strategy to Address Global Disparities in Access
作者：Eunjin Hong, Paul M. Beringer* (CHA University, South Korea; University of Southern California, USA)
2. 人工智能与疾病建模：重点关注神经系统疾病
Artificial Intelligence and Disease Modeling: Focus on Neurological Disorders
作者：Benjamin Ribba* (F. Hoffmann-La Roche Ltd., Switzerland)

Reviews（综述）
1. 腺相关病毒载体视网膜基因治疗的药物学发展视角
Clinical Pharmacology Perspective on Development of Adeno-Associated Virus Vector-Based Retina Gene Therapy
作者：Jennifer Lynn Ford* (JSpring House, USA)
2.即用型同种异体细胞治疗的药物学考量
Clinical Pharmacology Considerations for the “Off-the-Shelf” Allogeneic Cell Therapies
作者：Hardik Mody* (Genentech, USA)
Mini Review（微综述）
1.妊娠期间生物制剂使用的利-险概念框架：一项微综述
A Benefit–Risk Conceptual Framework for Biologic Use During Pregnancy: A Mini-Review
作者：Laura M. Bozzi* （Raritan, USA）
Systematic Review（系统综述）
1.治疗方式和给药途径对复发或难治性多发性骨髓瘤细胞因子释放综合征影响的Meta分析
mpact of Treatment Modality and Route of Administration on Cytokine Release Syndrome in Relapsed or Refractory Multiple Myeloma: A Meta-Analysis
作者：Pooneh Soltantabar, Mohamed Elmeliegy* (Pfizer Inc, USA)
2.真实世界证据指导监管决策制定：一项范围综述
Real-World Evidence to Inform Regulatory Decision Making: A Scoping Review
作者：Marieke S. Jansen* (Leiden University Medical Center, The Netherlands)
Brief Report （简报）
1.吸烟戒断药物副作用的遗传预测：伐尼克兰异常梦境的全基因组研究
Genetic Prediction of Smoking Cessation Medication Side Effects: A Genome-Wide Investigation of Abnormal Dreams on Varenicline
作者：Meghan J. Chenoweth* (Centre for Addiction and Mental Health, Canada)
Articles（文章）
1.个性化时序调节5-氟尿嘧啶治疗：一种生理学基础药代动力学精准剂量方法，用于优化癌症治疗
Personalized Chronomodulated 5-Fluorouracil Treatment: A Physiologically-Based Pharmacokinetic Precision Dosing Approach for Optimizing Cancer Therapy
作者：Fatima Zahra Marok, Thorsten Lehr* (Saarland University, Germany)
2.风险评估和缓解策略如何影响临床实践？全国医师调查
How Do Risk Evaluation and Mitigation Strategies Impact Clinical Practice? A National Survey of Physicians
作者：Ameet Sarpatwari* (Brigham and Women's Hospital, USA)
3.SGLT-2 抑制剂使用与特定原因住院率：一项广泛结果研究，以识别SGLT-2 抑制剂的新关联
SGLT-2 Inhibitor Use and Cause-Specific Hospitalization Rates: An Outcome-Wide Study to Identify Novel Associations of SGLT-2 Inhibitors
作者：George S. Q. Tan*, Jenni Ilomäki* (Monash University, Australia)
4.随机试验比较标准护理与贝叶斯法华法林剂量个体化
A Randomized Trial Comparing Standard of Care to Bayesian Warfarin Dose Individualization
作者：Ling Xue, Liyan Miao* (The First Affiliated Hospital of Soochow University, China)
5.口服SSTR5拮抗剂SCO-240对生长激素刺激作用的研究：一项在健康个体中的I期单剂量研究
Oral SSTR5 Antagonist SCO-240 for Growth Hormone Stimulation: A Phase I Single-Dose Study in Healthy Individuals
作者：Harunobu Nishizaki, Tomoya Kagawa, Jun Sugama, Yusuke Moritoh*, Masanori Watanabe* (SCOHIA PHARMA Inc., Japan)
6.达普司他药物相互作用和药代动力学在肝功能障碍和慢性肾脏病中的机制决定因素：OATP1B-CYP2C8相互作用的重要性
Mechanistic Determinants of Daprodustat Drug–Drug Interactions and Pharmacokinetics in Hepatic Dysfunction and Chronic Kidney Disease: Significance of OATP1B-CYP2C8 Interplay
作者：Yi-An Bi, Manthena V. S. Varma* (Pfizer Inc., USA)
7.亚洲包容性全球开发恩帕托兰：一项族群桥接研究、内在/外在因素评估和疾病轨迹建模的结果，为II期多区域临床试验设计提供信息
Asia-Inclusive Global Development of Enpatoran: Results of an Ethno-Bridging Study, Intrinsic/Extrinsic Factor Assessments and Disease Trajectory Modeling to Inform Design of a Phase II Multiregional Clinical Trial
作者：Lena Klopp-Schulze* (the healthcare business of Merck KGaA, Germany)
8.别嘌醇对老年高尿酸血症患者脑卒中和心血管事件的影响：随机对照试验的后设分析
Impacts of Febuxostat on Cerebral and Cardiovascular Events in Elderly Patients with Hyperuricemia: Post Hoc Analysis of a Randomized Controlled Trial
作者：Masahiro Sugawara, Sunao Kojima* (Sugawara Clinic, Japan; Sakurajyuji Yatsushiro Rehabilitation Hospital, Japan)
9.荷兰药物召回对患者影响的研究：一项为期5年的回顾性数据分析
Impact of Drug Recalls on Patients in The Netherlands: A 5-Year Retrospective Data Analysis
作者：Pieter A. Annema* (Jeroen Bosch Hospital, The Netherlands)
10.自适应平台试验与多个独立试验相比效率提高了多少？为在大流行期间简化药物开发而进行的全面模拟研究
How Much More Efficient Are Adaptive Platform Trials Than Multiple Stand-Alone Trials? A Comprehensive Simulation Study for Streamlining Drug Development During a Pandemic
作者：Masanao Sasaki, Hiroyuki Sato, Akihiro Hirakawa* (Tokyo Medical and Dental University (TMDU), Japan)
11.1型糖尿病患者使用胰岛素泵治疗的混合餐耐量试验反应的随机交叉试验：YG1699与达格列净的比较
A Randomized Crossover Trial of Mixed Meal Tolerance Test Response in People with Type 1 Diabetes on Insulin Pump Therapy and YG1699 or Dapagliflozin
作者：Pablo Lapuerta* (Youngene Therapeutics Co., Ltd., China)
12.使用大型语言模型从临床笔记中算法识别治疗中出现的不良事件：炎症性肠病的试点研究
Algorithmic Identification of Treatment-Emergent Adverse Events From Clinical Notes Using Large Language Models: A Pilot Study in Inflammatory Bowel Disease
作者：Anna L. Silverman¹, Madhumita Sushil², Balu Bhasuran², Vivek A. Rudrapatna²* (1. Mayo Clinic, USA; 2. Bakar Computational Health Sciences Institute, USA)
13.中国监管改革对药物滞后的影响：临床开发策略的作用
The Impact of Regulatory Reforms in China on Drug Lag: The Role of Clinical Development Strategies
作者：Yue Han, Rong Jiang, Rong Shao*, Jinping Xie* (China Pharmaceutical University, China)
14.利尿剂诱导的高尿酸血症、高血糖和尿电解质紊乱的遗传决定因素 - 基于英国生物银行的全基因组评估
Genetic Determinants of Thiazide-Induced Hyperuricemia, Hyperglycemia, and Urinary Electrolyte Disturbances – A Genome-Wide Evaluation of the UK Biobank
作者：Innocent G. Asiimwe*, Munir Pirmohamed* (University of Liverpool, UK)
15.中重度活动性溃疡性结肠炎患者中使用古塞库单抗和戈利木单抗的联合治疗：药代动力学、免疫原性和药物-药物相互作用
Combination Therapy With Guselkumab and Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Pharmacokinetics, Immunogenicity and Drug–Drug Interactions
作者：Jie Shao, Zhenhua Xu* (Spring House, USA)
16.阿托伐他汀药代动力学的全基因组关联研究：与SLCO1B1、UGT1A3和LPP的关联
Genome-Wide Association Study of Atorvastatin Pharmacokinetics: Associations With SLCO1B1, UGT1A3, and LPP
作者：Anssi J.H. Mykkänen, Mikko Niemi* (University of Helsinki, Finland)
17.达格列净降低慢性肾脏病患者的尿液肾脏损伤生物标志物，与白蛋白尿水平无关
Dapagliflozin Reduces Urinary Kidney Injury Biomarkers in Chronic Kidney Disease Irrespective of Albuminuria Level
作者：Junghyun Cho, Soon Hyo Kwon* (Soonchunhyang University Seoul Hospital, Korea)
18.HIV感染者实际人群中口服卡博特韦和长效肌肉注射卡博特韦的群体药代动力学
Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long-Acting Intramuscular Injection in Real-World People with HIV
作者：Paul Thoueille, Monia Guidi* (Lausanne University Hospital and University of Lausanne, Switzerland)

二、药理学评论

（本刊为双月刊，每两月更新一次，详见2024年8月更新）

三、先进药物输送评论 (2024年第209卷)

June 2024 - Volume 209 (2024年6月第209卷)
https://www.sciencedirect.com/journal/advanced-drug-delivery-reviews/vol/209/suppl/C

Review article（综述文章）
1.纳米颗粒与淋巴系统的相互作用：药物传递中的机制与应用
Interactions between nanoparticles and lymphatic systems: Mechanisms and applications in drug delivery
作者：Yisi Tang¹, Bao Liu¹, Yuting Zhang¹, Yongzhuo Huang²*, Wufa Fan¹* (1. Chinese Academy of Medical Sciences & Peking Union Medical College, China; 2. Chinese Academy of Sciences, China)
2.非病毒载体靶向囊性纤维化治疗的新时代
A new era of targeting cystic fibrosis with non-viral delivery of genomic medicines
作者：Namratha Turuvekere Vittala Murthy, Gaurav Sahay* (College of Pharmacy at Oregon State University, USA)
3.纤维连接蛋白在自身免疫和纤维化治疗中的靶向递送技术
Delivery technologies for therapeutic targeting of fibronectin in autoimmunity and fibrosis applications
作者：Jacob D. Bonadio, Karin Wang* (Temple University, United States)
4.向更易接受的皮下注射迈进：改善组合产品设计的促进因素综述
Towards more tolerable subcutaneous administration: Review of contributing factors for improving combination product design
作者：Neil Mathias, Sylvain Huille* (Bristol-Myers Squibb, Co., USA; Sanofi, France)
5.通过siRNA基因沉默实现免疫检查点阻断的癌症免疫疗法进展
Advancing cancer immunotherapy through siRNA-based gene silencing for immune checkpoint blockade
作者：Youngjin Choi, Su Hyun Seok, Ju Hee Ryu*, Ick Chan Kwon* (Korea Institute of Science and Technology (KIST), Republic of Korea)
6.细胞膜包覆的纳米颗粒用于靶向致癌细菌
Cell membrane-coated nanoparticles for targeting carcinogenic bacteria
作者：Lei Sun, Weiwei Gao*, Liangfang Zhang* (University of California San Diego, USA)
7.角膜纤维化：从体外模型到当前和即将推出的药物和基因药物
Corneal fibrosis: From in vitro models to current and upcoming drug and gene medicines
作者：Laura Trujillo Cubillo, Dimitrios I. Zeugolis* (University College Dublin (UCD), Ireland)
8.改善类风湿关节炎治疗的局部药物递送技术进展
Advances in local drug delivery technologies for improved rheumatoid arthritis therapy
作者：Xiaoran An, Jiapei Yang, Xiaolin Cui, Jiaxuan Zhao, Feihu Wang* (Shanghai Jiao Tong University, PR China)
9.梭杆菌属核酸杆菌致癌作用及药物递送干预
Fusobacterium nucleatum carcinogenesis and drug delivery interventions
作者：Zhenzhen Chen, Leaf Huang* (The University of North Carolina at Chapel Hill, United States)
10.聚焦超声诱导的血脑屏障开放在神经退行性疾病临床应用中的进展
Recent advances of focused ultrasound induced blood-brain barrier opening for clinical applications of neurodegenerative diseases
作者：Pengxuan Zhao¹, Tiantian Wu², Xinwu Cui¹* (1. Huazhong University of Science and Technology, China; 2. Hainan Medical University, China)
11.CCL2/CCR2轴在癌症和炎症中的作用：纳米医学的下一个前沿
The role of CCL2/CCR2 axis in cancer and inflammation: The next frontier in nanomedicine
作者：Sabina Pozzi, Ronit Satchi-Fainaro* (Weizmann Institute of Science, Israel; Tel Aviv University, Israel)
12.利用生物材料推进免疫疗法：控制皮肤中的组织、细胞和分子水平的免疫信号
Advancing immunotherapy using biomaterials to control tissue, cellular, and molecular level immune signaling in skin
作者：Shrey A. Shah, Christopher M. Jewell* (University of Maryland, USA)
13.纳米颗粒-中性粒细胞相互作用在自身免疫调节中的应用
Nanoparticle-neutrophils interactions for autoimmune regulation
作者：Daniel Kupor, Omolola Eniola-Adefeso* (University of Michigan, USA)
14.从细胞到亚细胞器：基于肽自组装的下一代癌症疗法
From cells to subcellular organelles: Next-generation cancer therapy based on peptide self-assembly
作者：Huayang Liu, Huaimin Wang* (Westlake University, China)
15.制药和生物技术行业视角：通过皮下药物递送设计优化患者体验和治疗依从性
Pharmaceutical and biotech industry perspectives on optimizing patient experience and treatment adherence through subcutaneous drug delivery design
作者：Jennifer Stevenson* (Amgen, USA)

四、药理学发展趋势 (2024年第45卷第6期)

June 2024 - Volume 45 - Issue 6 (2024年6月第45卷第6期)
https://www.cell.com/trends/pharmacological-sciences/issue?pii=S0165-6147(23)X0007-8#closeFullCover

Spotlight（聚焦）
1.马洛内酯的突破：K-Ras-G12D的致命弱点
Malolactone strikes: K-Ras-G12D's Achilles' heel
作者：Christos Adamopoulos, Athanasios G. Papavassiliou* (National and Kapodistrian University of Athens, Greece)
2.增强致癌信号以杀死癌细胞
Enhancing oncogenic signaling to kill cancer cells
作者：Maxim Noeparast* (II. Med Clinics Hematology and Oncology, Germany)
Opinion（观点）
1.TNIK在癌症、代谢和与年龄相关疾病中的新兴作用
TNIK’s emerging role in cancer, metabolism, and age-related diseases
作者：Collin Y. Ewald, Alex Zhavoronkov* (ETH Zürich, Switzerland; Insilico Medicine US Inc., USA)
Reviews（综述）
1.通过药物组合或双靶点药物战胜MYC
Defeating MYC with drug combinations or dual-targeting drugs
作者：Philip E. Thompson* (Monash University, Australia)
2.抗癌药物：如何选择小分子组合？
Anticancer drugs: How to select small molecule combinations?
作者：Ruth Nussinov* (Frederick National Laboratory for Cancer Research, Frederick, USA)
3.免疫检查点阻断在肺癌中的抗性：新兴机制与治疗机会
Immune checkpoint blockade resistance in lung cancer: emerging mechanisms and therapeutic opportunities
作者：Jessica M. Konen*, Don L. Gibbons* (Emory University, USA; University of Texas MD Anderson Cancer Center, USA)
4.癌症治疗中脂质代谢的新兴靶点
Emerging targets in lipid metabolism for cancer therapy
作者：Alexander R. Terry*, Nissim Hay* (Memorial Sloan Kettering Cancer Center, USA; University of Illinois at Chicago, USA)

五、药理学与治疗学 (2024年第258卷)

June 2024 - Volume 258 (2024年6月第258卷)
https://www.sciencedirect.com/journal/pharmacology-and-therapeutics/vol/258/suppl/C

Review article（综述文章）
1.治疗癌症中DNA甲基化异常的靶向治疗
Therapeutic targeting of DNA methylation alterations in cancer
作者：Abigail V. Lee, Kevin A. Nestler, Katherine B. Chiappinelli* (The George Washington University, USA)
2.赛洛西宾用于预防痴呆症？赛洛西宾改变与重度抑郁和神经退行性疾病相关机制的潜在作用
Psilocybin for dementia prevention? The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases
作者：Zarah R. Haniff* (King's College London, United Kingdom)
3.心脏中CYP2J2介导的花生四烯酸代谢：对其动力学、抑制和在心律控制中作用的综述
CYP2J2-mediated metabolism of arachidonic acid in heart: A review of its kinetics, inhibition and role in heart rhythm control
作者：Jacqueline Wen Hui Leow, Eric Chun Yong Chan* (National University of Singapore, Singapore)
4.顺铂在PARP抑制剂和免疫疗法时代的应用
Cisplatin in the era of PARP inhibitors and immunotherapy
作者：Mingrui Duan, Shuguang Leng*, Peng Mao* (University of New Mexico, USA)
5.超微粉化的N-棕榈酰乙醇胺与镇痛药联合使用：对抗持续性疼痛的效果
Ultramicronized N-palmitoylethanolamine associated with analgesics: Effects against persistent pain
作者：Stefania Nobili*, Laura Micheli, Lorenzo Di Cesare Mannelli* (University of Florence, Italy)
6.环核苷酸在免疫中的药理学潜力
Pharmacological potential of cyclic nucleotide signaling in immunity
作者：Eirene Marie Q. Ednacot, Ali Nabhani, David M. Dinh, Benjamin R. Morehouse* (University of California Irvine, USA)

六、药物 (2024年第84卷第6期)

June 2024 - Volume 84 - Issue 6 (2024年6月第84卷第6期)

Leading Article （社论）
1.靶向系统性红斑狼疮中的干扰素信号通路：吸取的教训
Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned
作者：Sarah A. Jones, Eric F. Morand* (Monash University, Australia)
2.脂蛋白(a)抑制剂的治疗潜力
Therapeutic Potential of Lipoprotein(a) Inhibitors
作者：Stephen J. Nicholls* (Monash University, Australia)
Review Article（综述文章）
1.产后抑郁：影响及当前治疗解决方案的临床综述
Postpartum Depression: A Clinical Review of Impact and Current Treatment Solutions
作者：Cindy-Lee Dennis* (Lunenfeld-Tanenbaum Research Institute, Canada)
2.抗IL-5途径药物在全生命周期嗜酸性粒细胞相关疾病中的应用
Anti-IL-5 Pathway Agents in Eosinophilic-Associated Disorders Across the Lifespan
作者：Carlo Lombardi, Pasquale Comberiati, Alvise Berti* (Fondazione Poliambulanza, Italy; University of Pisa, Italy; University of Trento, Italy)
Systematic Review（系统综述）
1.性别对经皮冠状动脉介入治疗后双重抗血小板治疗结果的影响：成对和网络元分析Sex-Based Outcomes of Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention: A Pairwise and Network Meta-Analysis
作者：Thomas A. Agbaedeng* (University of Oxford, UK)
AdisInsight Report（AdisInsight报告）
1.Crovalimab：首次批准
Crovalimab: First Approval
Crovalimab（派圣凯®；PiaSky）是由中外制药与罗氏合作开发的一种人源化、抗补体成分C5（anti-C5）循环单克隆抗体，正在研究用于治疗补体介导的疾病，包括阵发性睡眠性血红蛋白尿（PNH）、非典型溶血性尿毒症综合征、狼疮性肾炎和镰状细胞病。Crovalimab靶向C5，抑制其裂解为C5a和C5b，从而阻断末端补体途径，预防PNH中的血管内溶血。Crovalimab旨在反复结合抗原，实现在较低剂量下持续的补体抑制，并允许每月一次皮下给药。2024年2月，皮下给药的Crovalimab在中国首次获得批准，用于治疗尚未接受过补体抑制剂治疗的青少年和成人（年龄≥12岁）PNH患者。此后，Crovalimab于3月在日本获得批准，用于治疗PNH患者，包括治疗初期和之前接受过治疗的患者。Crovalimab也正在接受美国和欧盟等多个国家的监管审查，用于治疗PNH的初期和之前接受过治疗的患者。本文总结了Crovalimab开发过程中的里程碑，这些里程碑导致了其在中国首次获得批准用于治疗PNH。
2. Tegileridine：首次批准
Tegileridine: First Approval
泰吉利定（艾苏特）是一种由江苏恒瑞医药股份有限公司开发的小分子μ-阿片受体偏向激动剂，用于治疗术后疼痛。泰吉利定选择性激活G蛋白偶联途径，这可以产生强烈的中枢镇痛效果，同时它只微弱激活与不良事件相关的β-arrestin-2途径，如呼吸抑制和胃肠功能障碍。2024年1月，泰吉利定在中国首次获得批准，用于治疗腹部手术后的中至重度疼痛。本文总结了泰吉利定开发过程中的重要里程碑，这些里程碑导致了其在中国首次获得批准用于治疗腹部手术后的中至重度疼痛。
3.Ensitrelvir Fumaric Acid：首次批准
Ensitrelvir Fumaric Acid: First Approval
恩西曲韦富马酸（Xocova®）是由盐野义制药研发的口服SARS-CoV-2主要蛋白酶抑制剂，用于治疗SARS-CoV-2感染。它是同类中首个单一实体、非肽类、非共价、小分子抗病毒药物。在2022年11月在日本获得紧急监管批准后，恩西曲韦于2024年3月5日在日本获得标准批准，用于治疗SARS-CoV-2感染。本文总结了恩西曲韦开发过程中的里程碑，这些里程碑导致了该药物首次获得针对SARS-CoV-2感染的标准批准。
4.Resmetirom：首次批准
Resmetirom: First Approval
Resmetirom（商品名Rezdiffra™）是由Madrigal Pharmaceuticals, Inc.开发的一种口服甲状腺激素受体-β（THR-β）激动剂，旨在针对与代谢功能障碍相关的脂肪肝病（MASH）[之前称为非酒精性脂肪肝病（NASH）]的关键根本原因。2024年3月，resmetirom在美国获得加速批准，与饮食和运动结合使用，用于治疗非肝硬化性NASH的成年患者，这些患者具有中度至重度肝纤维化（符合F2至F3阶段的纤维化）。Resmetirom也在欧盟接受监管审查，用于治疗MASH/NASH。本文总结了resmetirom开发过程中的里程碑，这些里程碑导致了其首次获得批准用于治疗成年MASH/NASH患者。
5.Cefepime/Enmetazobactam：首次批准
Cefepime/Enmetazobactam: First Approval
Cefepime/enmetazobactam（商品名EXBLIFEP®），是一种静脉注射（IV）的抗菌固定剂量组合，由第四代头孢菌素和广谱β-内酰胺酶（ESBL）抑制剂组成，由Allecra Therapeutics和ADVANZ PHARMA开发，用于治疗由多药耐药（MDR）革兰阴性菌引起的感染。2024年2月，cefepime/enmetazobactam在美国获得批准，用于治疗成人复杂性尿路感染（cUTI），包括由大肠杆菌、克雷伯菌、铜绿假单胞菌、奇异变形杆菌和阴沟肠杆菌复合群引起的肾盂肾炎。2024年3月，cefepime/enmetazobactam在欧盟获得批准，用于成人治疗cUTI（包括肾盂肾炎）、医院获得性肺炎（包括呼吸机相关肺炎），以及治疗与这些感染相关或疑似相关的菌血症患者。本文总结了cefepime/enmetazobactam开发过程中的里程碑，这些里程碑导致了其首次获得批准用于治疗由MDR革兰阴性菌引起的成人感染。

七、药理学研究 (2024年第204卷)

June 2024 - Volume 204 (2024年6月第204卷)
https://www.sciencedirect.com/journal/pharmacological-research/vol/204/suppl/C

Review Articles（综述文章）
1.DNA和RNA鸟苷氧化在心血管疾病中的作用
The role of DNA and RNA guanosine oxidation in cardiovascular diseases
作者：Yiping Li, Xiaolong Wang* (Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, China)
2.eEF1A蛋白在癌症中的作用：临床意义、致癌机制和靶向治疗策略
The eEF1A protein in cancer: Clinical significance, oncogenic mechanisms, and targeted therapeutic strategies
作者：Weicheng Zhang*, Changliang Shan* (Nankai University, People's Republic of China)
3.巨噬细胞和肿瘤相关巨噬细胞在衰老微环境中的作用：从免疫抑制的肿瘤微环境到靶向肿瘤治疗
Macrophages and tumor-associated macrophages in the senescent microenvironment: From immunosuppressive TME to targeted tumor therapy
作者：Ming Du¹, Lu Sun¹, Jinshuai Guo²*, Huina Lv¹* (Shengjing Hospital of China Medical University, China; Fourth Affiliated Hospital of China Medical University, China)
4.TNFAIP2作为癌症治疗中的新兴治疗靶点及其潜在机制
TNFAIP2 as an emerging therapeutic target in cancer therapy and its underlying mechanisms
作者：Zhanqi Fu, Yuan Yuan* (the First Hospital of China Medical University, China)
5.植物源性细胞外囊泡在骨骼肌肉系统研究进展
Advances in the study of plant-derived extracellular vesicles in the skeletal muscle system
作者：Xinning Mao¹, Tenghui Li¹, Weihui Qi¹, Hongting Jin²*, Hao Pan¹*, Dong Wang¹* (Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University (1. Hangzhou Hospital of Traditional Chinese Medicine), PR China; 2. The First Affiliated Hospital of Zhejiang Chinese Medical University, China)
6.揭示雌激素的潜力：探索其在神经精神疾病及运动干预中的作用
Unveiling the potential of estrogen: Exploring its role in neuropsychiatric disorders and exercise intervention
作者：Wenke He, Sen Zhang, Zhengtang Qi*, Weina Liu* (East China Normal University, China)
7.靶向LRP6：癌症治疗的新策略
Targeting LRP6: A new strategy for cancer therapy
作者：Wei Xue¹, Bo Zhu1, Zhaoquan Huang²*, Hongwei Guo¹* (1. Guangxi Medical University, China; 2. The First Affiliated Hospital of Guangxi Medical University, China)
8.特定神经元群体中烟碱型乙酰胆碱受体的表达与功能：重点关注纹状体和前额叶回路
Expression and function of nicotinic acetylcholine receptors in specific neuronal populations: Focus on striatal and prefrontal circuits
作者：Alice Abbondanza, Helena Janickova* (Institute of Physiology of the Czech Academy of Sciences, Czech Republic)
9.人参皂苷对免疫系统的多层次作用
Multi-layered effects of Panax notoginseng on immune system
作者：Chunhao Yang, Fengkun Xiao* (Yunnan Yunke Characteristic Plant Extraction Laboratory Co., Ltd., China)
10.TREM1：激活、信号传导、癌症与治疗
TREM1: Activation, signaling, cancer and therapy
作者：Chenyang Li, Chujun Cai, Xiaoping Chen*, Jia Song* (Huazhong University of Science and Technology, China)
11.免疫蛋白酶体在心血管疾病中的作用
The role of the immunoproteasome in cardiovascular disease
作者：Yifei Nie¹, Dongfeng Zhang¹*, Hui-Hua Li²*, Xiantao Song¹* (1. Beijing Anzhen Hospital, Capital Medical University, China; 2. Beijing Chao-Yang Hospital, Capital Medical University, China)
12.三阴性乳腺癌的表观遗传调控：对肿瘤微环境的治疗意义
Epigenetic modulations in triple-negative breast cancer: Therapeutic implications for tumor microenvironment
作者：Linlin Zhou, Chen-Wei Yu* (Fujian Medical University, China; Fu Jen Catholic University, Taiwan, China)
13.促炎细胞因子和CXC趋化因子在老年前列腺癌和卵巢癌中作为游戏规则改变者：来自临床前和临床研究结果的见解
Pro-inflammatory cytokines and CXC chemokines as game-changer in age-associated prostate cancer and ovarian cancer: Insights from preclinical and clinical studies' outcomes
作者：Amin Ullah¹, Yongxiu Chen², Bairong Shen¹* (1. Cancer Center of West China Hospital and Institutes for Systems Genetics, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, China; 2. Guangdong Women and Children Hospital, China)
14.心力衰竭患者使用血管紧张素受体阻滞剂-脑啡肽酶抑制剂：针对左心室射血分数降低的临床应用
Angiotensin receptor blocker-neprilysin inhibitor for heart failure with reduced ejection fraction
作者：Dima Nasrallah, Ali H. Eid* (Qatar University, Qatar)
15.针对JAK-STAT通路的小分子药物发现
Small molecule drug discovery targeting the JAK-STAT pathway
作者：You Lv¹, Pengbing Mi²*, Faming Wang¹*, Bostjan Kobe³* (1. Xi’an University of Science and Technology, China; 2. Hengyang Medical School, University of South China, China; 3. University of Queensland, Australia)
Research article（研究文章） 
1.环状RNA CDR1as影响脊髓损伤后的功能修复并通过SMAD通路调节纤维化
CircRNA CDR1as affects functional repair after spinal cord injury and regulates fibrosis through the SMAD pathway
作者：Wenzhao Wang¹, Chang Liu², Dong He³, Jianlu Wei¹*, Yunpeng Jiang¹*, Liang Ma²* (1. Qilu Hospital of Shandong University, China; 2. The First Affiliated Hospital of Chongqing Medical University, China; 3. Shandong Provincial Hospital Affiliated to Shandong First Medical University, China)
2.黄芩素对早期抗生素治疗后肠道损伤的修复作用：MAPK信号通路的角色
Baicalin restore intestinal damage after early-life antibiotic therapy: the role of the MAPK signaling pathway
作者：Shunfen Zhang, Shanlong Tang, Zhengqun Liu, Ruqing Zhong*, Liang Chen* (Chinese Academy of Agricultural Sciences, China)
3.SARS-CoV-2在COVID-19中对线粒体代谢和表观基因组的重编程
SARS-CoV-2 mitochondrial metabolic and epigenomic reprogramming in COVID-19
作者：Joseph W. Guarnieri, Douglas C. Wallace* (The Children's Hospital of Philadelphia, USA)
4.解析中国大陆胰腺癌微生物组：Exiguobacterium/Bacillus比例对肿瘤进展和预后意义的影响
Deciphering the pancreatic cancer microbiome in Mainland China: Impact of Exiguobacterium/Bacillus ratio on tumor progression and prognostic significance
作者：Zhengyan Zhang¹, Ting Wang², Ming Xu³, Huaizhi Wang⁴*, Jing Xue¹*, Wei Wang⁵* (1. Ren Ji Hospital, Shanghai Cancer Institute, Shanghai Jiao Tong University School of Medicine, China; 2. Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, China; 3. Shanghai Hongkou District Jiangwan Hospital, China; 4. Chongqing General Hospital, Chongqing University, China; 5. Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, China)
5.时间依赖性蛋白质组学及癌细胞扩增中的药物反应
Time-dependent proteomics and drug response in expanding cancer cells
作者：Yuting Pan¹, Ying Xuan¹, Piliang Hao², Xisong Ke¹*, Yi Qu¹*, Xue Zhang¹* (1. Shanghai University of Traditional Chinese Medicine, PR China; 2. ShanghaiTech University, PR China)
6.降低循环IPA水平可识别具有代谢共病的个体：一项多组学研究
Decreased circulating IPA levels identify subjects with metabolic comorbidities: A multi-omics study
作者：Marta Ballanti¹, Lorenzo Antonetti², Massimo Federici¹* (1. Policlinico Tor Vergata University Hospital, Italy; 2. University of Rome Tor Vergata, Italy)
7.蛋白质组学分析确定新抗原和细菌肽作为结直肠癌免疫治疗的靶点
Proteogenomic analysis identifies neoantigens and bacterial peptides as immunotherapy targets in colorectal cancer
作者：Pengju Yao, Jianguo Ji* (Peking University, China)
8.METTL14依赖的m6A修饰通过miR-186–3p/MAP3K9轴下调CircUGGT2抑制胃癌进展和顺铂抗性
CircUGGT2 downregulation by METTL14-dependent m6A modification suppresses gastric cancer progression and cisplatin resistance through interaction with miR-186–3p/MAP3K9 axis
作者：Xiao-Yu Chen, Yan-Ling Yang, Jing Zhang*, Jin-Shui Zhu* (Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, China)
9.甜味剂的时间特性的药理学视角
A Pharmacological perspective on the temporal properties of sweeteners
作者：Guy Servant* (dsm-firmenich, USA)
10.靶向肿瘤circ-E-钙粘蛋白编码的C-E-钙粘蛋白抑制乳腺癌相关骨髓来源抑制细胞的招募和功能
Targeting tumorous Circ-E-Cadherinencoded C-E-Cad inhibits the recruitment and function of breast cancer-associated myeloid-derived suppressor cells
作者：Junyi Zhou¹, Hao Xu², Xixi Li³, Zicheng Sun⁴, Xinya Gao¹* (1. Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangdong Provincial Clinical Research Center for Child Health, China; 2. Shandong Provincial Hospital Affiliated to Shandong First Medical University, China; 3. The First Affiliated Hospital of Sun Yat-sen University, China; 4. Qilu Hospital of Shandong University, China)
11.通过四方国家自我评估调查（TrACSS）追踪G7国家2017至2023年抗菌素耐药性的进展：机遇与差距
Tracking progress on antimicrobial resistance by the quadripartite country self-assessment survey (TrACSS) in G7 countries, 2017–2023: opportunities and gaps
作者：Michela Sabbatucci* (Ministry of Health, Italy)
12.基于“进化陷阱”克服肿瘤药物抗性的CAR-T疗法靶点扩展
Expand available targets for CAR-T therapy to overcome tumor drug resistance based on the "Evolutionary Traps"
作者：Xu Wang¹, Xu Wang¹, Dan Liu¹*, Junnian Zheng²*, Ming Shi¹* (1. Xuzhou Medical University, China; 2. The Affiliated Hospital of Xuzhou Medical University, China)
13.STC1与βPIX竞争性结合通过YAP核转位及通过YAP/CCL2/VEGFA/AKT反馈回路招募M2型巨噬细胞促进黑色素瘤进展
STC1 competitively binding βPIX enhances melanoma progression via YAP nuclear translocation and M2 macrophage recruitment through the YAP/CCL2/VEGFA/AKT feedback loop
作者：Zhaozhou Ren, Wan’an Xiao* (Shengjing Hospital of China Medical University, China)
14.口腔微生物群失调通过调节宿主代谢改变慢性束缚应激诱导的抑郁样行为
Oral microbiota dysbiosis alters chronic restraint stress-induced depression-like behaviors by modulating host metabolism
作者：Fangzhi Lou, Shihong Luo, Xin Jin* (Chongqing Medical University, China)

八、抗病毒研究 (2024年第226卷)

June 2024 - Volume 226 (2024年6月第226卷)
https://www.sciencedirect.com/journal/antiviral-research/vol/226/suppl/C

Research article（研究文章）
1.基于金属有机框架的药物递送系统提高了5-氟尿嘧啶对鲤春病毒病病毒的抗性
Drug delivery system based on metal-organic framework improved 5-Fluorouracil against spring viremia of carp virus
作者：Liang Zhao, Wei-Ze Wang, Bo Liu*, Bin Zhu* (Northwest A&F University, China)
2.吸入2,4-二叔丁基苯酚载药胶束抑制小鼠呼吸道合胞病毒感染
Inhalation of 2, 4-di-tert-butylphenol-Loaded micelles suppresses respiratory syncytial virus infection in mice
作者：Mingyang Guo¹, Jianqing Peng¹, Pengcheng Guo², Yu-Si Luo³*, Ke Zhang¹* (1. Guizhou Medical University, China; 2. Fudan University & Key Laboratory of Smart Drug Delivery, China; 3. The Affiliated Hospital of Guizhou Medical University, China)
3.抑制Pim激酶触发广泛的抗病毒活性，通过影响先天免疫和通过PI3K-Akt-mTOR轴影响内溶酶体系统
Inhibition of Pim kinases triggers a broad antiviral activity by affecting innate immunity and via the PI3K-Akt-mTOR axis the endolysosomal system
作者：Mirco Glitscher, Nuka Ivalu Benz, Eberhard Hildt* (Paul-Ehrlich-Institute, Germany)
4.转录因子阴阳1与乙型肝炎病毒复制之间的相互调控影响慢性乙型肝炎
A mutual regulatory loop between transcription factor Yin Yang 1 and hepatitis B virus replication influences chronic hepatitis B
作者：Jie Zhou, Xiaomei Wang*, Junqi Niu* (First Hospital of Jilin University, China)
5.PARADISE研究的中期分析：在NA治疗的CHB患者中附加聚乙二醇干扰素-α的益处
Interim analysis of the PARADISE study: Benefits of add-on peginterferon-α in NA-treated patients with CHB
作者：Shaowen Jiang, Simin Guo, Yan Huang, Qing Guo*, Haiguang Xin*, Qing Xie* (Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China)
6.一种异构体抑制剂对组蛋白去乙酰化酶2的阻断作用抑制乙型肝炎病毒共价闭合环状DNA的建立及其转录活性
An allosteric inhibitor of sirtuin 2 blocks hepatitis B virus covalently closed circular DNA establishment and its transcriptional activity
作者：Liudi Tang* (LLC, USA)
7.多氧金属酸盐对人类呼吸道病毒具有广谱活性，阻碍病毒进入
Polyoxometalate exerts broad-spectrum activity against human respiratory viruses hampering viral entry
作者：Irene Arduino, David Lembo* (Laboratory of Molecular Virology and Antiviral Research, University of Turin, Italy)
8.CK1和PP1通过L蛋白磷酸化调节裂谷热病毒基因组复制
CK1 and PP1 regulate Rift Valley fever virus genome replication through L protein phosphorylation
作者：Nicole Bracci¹, Alan Baer², Kylene Kehn-Hall¹* (1. Virginia Polytechnic Institute and State University, USA; 2. George Mason University, USA)
9.筛选和优化针对SARS-CoV-2刺突RBD的鲨鱼纳米抗体
Screening and optimization of shark nanobodies against SARS-CoV-2 spike RBD
作者：Xiaochun Liu¹, Yanqing Wang¹, Ximing Xu¹*, Yuchao Gu²* (1. Ocean University of China, China; 2. Qingdao University of Science and Technology, China)
10.双层协同作用的壳聚糖包覆聚乳酸-羟基乙酸纳米球装载核酸作为鼻内给药疫苗递送系统，以控制口蹄疫病毒的感染
Double synergic chitosan-coated poly (lactic-co-glycolic) acid nanospheres loaded with nucleic acids as an intranasally administered vaccine delivery system to control the infection of foot-and-mouth disease virus
作者：Xian Li, Zhong-wang Zhang, Xin-sheng Liu*, Li Pan* (National Foot-and-Mouth Diseases Reference Laboratory, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, China)
11.抗体被动免疫在预防或控制HBV/HDV感染的现状与未来应用
Current and future use of antibody-based passive immunity to prevent or control HBV/HDV infections
作者：Adam J. Gehring* (University Health Network, Canada)
12.埃博拉特异性治疗抗体从实验室到临床：ZMapp的例子
Ebola-specific therapeutic antibodies from lab to clinic: The example of ZMapp
作者：Gary Wong, Ara XIII* (Virology Unit, Institut Pasteur Du Cambodge, Cambodia; University of Texas Medical Branch, USA）

九、英国药理学杂志 (2024年第181卷第11-12期)

（一）June 2024 - Volume 181 - Issue 11 (2024年6月第181卷第11期)
https://bpspubs.onlinelibrary.wiley.com/toc/14765381/2024/181/11

Mini Review （微综述）
1.2023年EMA、FDA和MHRA批准的新药：年度回顾
Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: A year in review
作者：Andreas Papapetropoulos* (National and Kapodistrian University of Athens, Greece)
Research Articles （研究文章）
1.Piezo1介导的平滑肌细胞体积调节对增强的细胞外基质刚性反应
Piezo1-mediated regulation of smooth muscle cell volume in response to enhanced extracellular matrix rigidity
作者：Robert T. Johnson, Derek T. Warren* (University of East Anglia, UK)
2.燕麦β-葡聚糖通过Dectin-1上调表皮分化、细胞间连接和脂质水平修复表皮屏障
Oat β-glucan repairs the epidermal barrier by upregulating the levels of epidermal differentiation, cell–cell junctions and lipids via Dectin-1
作者：Rongrong Jing, Xiaokun Li*, Zhiming Li*, Shuang Gao* (Wenzhou Medical University, China)
3.白藜芦醇，一种新型的脂肪酸结合蛋白5抑制剂，通过抑制脂肪酸转运至细胞核和下游途径抑制宫颈癌转移
Resveratrol, a novel inhibitor of fatty acid binding protein 5, inhibits cervical cancer metastasis by suppressing fatty acid transport into nucleus and downstream pathways
作者：Xiao Chen*, Bo Zhu*, Zichun Hua* (China Pharmaceutical University, China)
4.细胞外ATP通过P2X4受体抑制小清蛋白阳性中间神经元上的兴奋性突触输入并减弱γ振荡
Extracellular ATP inhibits excitatory synaptic input on parvalbumin positive interneurons and attenuates gamma oscillations via P2X4 receptors
作者：Florian Wildner, Zoltan Gerevich* (corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Germany)
5.丁酸作为5-HT转运体的正性别构调节剂，通过减少回肠中5-HT的可用性
Butyrate acts as a positive allosteric modulator of the 5-HT transporter to decrease availability of 5-HT in the ileum
作者：Jieling Cai, Connie W. Woo* (The University of Hong Kong, China)
6.阿亚瓦斯卡增强恐惧行为的消退：下丘脑皮层5-HT2A和5-HT1A受体的作用
Ayahuasca-enhanced extinction of fear behaviour: Role of infralimbic cortex 5-HT2A and 5-HT1A receptors
作者：Isabel Werle, Leandro J. Bertoglio* (Universidade Federal de Santa Catarina, Brazil)

（二）June 2024 - Volume 181 - Issue 12 (2024年6月第181卷第12期)
https://bpspubs.onlinelibrary.wiley.com/toc/14765381/2024/181/12

1.依鲁莫单抗在人离体冠状动脉和脑膜动脉中的药理学：在依鲁莫单抗最大效应基础上加用吉普坦类药物的额外效应
Pharmacology of erenumab in human isolated coronary and meningeal arteries: Additional effect of gepants on top of a maximum effect of erenumab
作者：Tessa de Vries, Antoinette MaassenVanDenBrink* (Erasmus University Medical Center, The Netherlands)
2.一种用于治疗神经痛的口服Cav2.2钙通道抑制剂
An orally available Cav2.2 calcium channel inhibitor for the treatment of neuropathic pain
作者：Janine Kutzsche, Dieter Willbold* (Forschungszentrum Jülich GmbH, Germany)
3.为什么忽略变构性的古典受体理论能够有效测量变构效应的强度作为激动剂的效能
Why classical receptor theory, which ignores allostery, can effectively measure the strength of an allosteric effect as agonist's efficacy
作者：H. Ongun Onaran* ( Ankara University, Turkey)
4.人参皂苷通过重塑宿主-微生物组代谢稳态延缓动脉粥样硬化
Ginsenosides retard atherogenesis via remodelling host–microbiome metabolic homeostasis
作者：Yun Wang¹, Aiqin Jiang²*, Haiping Hao¹*, Lijuan Cao¹* (1. China Pharmaceutical University, China; 2. Medical School of Nanjing University, China)
5.电压调节mGlu5受体功能，影响突触传递
Voltage tunes mGlu5 receptor function, impacting synaptic transmission
作者：Marin Boutonnet, Julie Perroy* (University of Montpellier, France)
6.补体调节谷氨酸释放并在多发性硬化症动物模型中支持突触损伤
Complement tunes glutamate release and supports synaptic impairments in an animal model of multiple sclerosis
作者：Guendalina Olivero, Anna Pittaluga* (University of Genoa, Italy)
7.胰岛素增敏剂是治疗1型糖尿病的新策略吗？一种长效的双阿米林和降钙素受体激动剂改善了胰岛素介导的血糖控制并控制了体重
Are insulin sensitizers the new strategy to treat Type 1 diabetes? A long-acting dual amylin and calcitonin receptor agonist improves insulin-mediated glycaemic control and controls body weight
作者：Simone Anna Melander* (Nordic Bioscience, Denmark)
8.安德罗格拉菲醇通过干扰p300调节H3组蛋白乳酸化以减轻主动脉瓣钙化
Andrographolide regulates H3 histone lactylation by interfering with p300 to alleviate aortic valve calcification
作者：Chunli Wang, Kang Xu* (Hubei University of Chinese Medicine, China)
9.来自日本刺参的全毒素A1通过诱导白色念珠菌的氧化损伤抑制口咽部和腹腔内念珠菌病
Holotoxin A1 from Apostichopus japonicus inhibited oropharyngeal and intra-abdominal candidiasis by inducing oxidative damage in Candida albicans
作者：Min Liao, Lei Cheng*, Biao Ren* (Sichuan University, China)
10.利用体内人类葡萄糖调节定量系统药理学模型对Cotadutide的双重GLP-1/胰高血糖素受体激动效应进行糖控制特性研究
Characterisation of cotadutide's dual GLP-1/glucagon receptor agonistic effects on glycaemic control using an in vivo human glucose regulation quantitative systems pharmacology model
作者：Rolien Bosch* (LAP&P Consultants, The Netherlands)
Short Report （短篇报告）
1.Radiprodil，一种选择性GluN2B负别构调节剂，挽救了携带GluN2A(N615S)突变的小鼠的音响源性癫痫
Radiprodil, a selective GluN2B negative allosteric modulator, rescues audiogenic seizures in mice carrying the GluN2A(N615S) mutation
作者：Ilaria Bertocchi* (University of Turin, Italy)

十、临床药代动力学 (2024年第63卷第6期)

June 2024 -Volume 63 - Issue 6 (2024年6月第63卷第6期)
https://link.springer.com/journal/40262/volumes-and-issues/63-6

Current Opinion （观点）
1.利用内源性生物标记物在药物开发中简化肾转运体介导的药物-药物相互作用评估：制药工业视角
Utilising Endogenous Biomarkers in Drug Development to Streamline the Assessment of Drug–Drug Interactions Mediated by Renal Transporters: A Pharmaceutical Industry Perspective
作者：Hee Jae Choi, Fenglei Huang* (Boehringer Ingelheim Pharmaceuticals, Inc., USA)
Review Article（综述文章）
1.Vericiguat的临床药代动力学和药效学特性
Clinical Pharmacokinetic and Pharmacodynamic Profile of Vericiguat
作者：Achim Fritsch* (Bayer AG, Germany)
Systematic Review（系统综述）
1.整体还是分开？揭示饮食干预对喹诺酮类药物生物利用度影响的系统综述与荟萃分析
Together or Apart? Revealing the Impact of Dietary Interventions on Bioavailability of Quinolones: A Systematic Review with Meta-analyses
作者：Agnieszka Wiesner, Paweł Paśko* (Jagiellonian University Medical College, Poland)
Original Research Article（原创研究文章）
1.一周一次的胰岛素Icodec在不同程度肾或肝功能损害对药代动力学特性的影响
The Effect of Various Degrees of Renal or Hepatic Impairment on the Pharmacokinetic Properties of Once-Weekly Insulin Icodec
作者：Hanne Haahr, Janne R. Hingst* (Novo Nordisk, Denmark)
2.开发糖尿病人群的生理药代动力学模型及其在理解疾病-药物-药物相互作用中的应用
Development of a Physiologically Based Pharmacokinetic Population Model for Diabetic Patients and its Application to Understand Disease-drug–drug Interactions
作者：Yafen Li, Xueting Yao*, Dongyang Liu* (Peking University Third Hospital, China)
3.去甲肾上腺素输注对子痫前期患者剖宫产腰麻下产妇低血压的剂量反应研究
Dose-Response Study of Norepinephrine Infusion for Maternal Hypotension in Preeclamptic Patients Undergoing Cesarean Delivery Under Spinal Anesthesia
作者：Yi Chen, Lei Guo, Xinli Ni* (General Hospital of Ningxia Medical University, 804S Shengli Street, China)
4.转移性肾细胞癌患者中卡博替尼的群体药代动力学：走向节省药物费用的方案
Population Pharmacokinetics of Cabozantinib in Metastatic Renal Cell Carcinoma Patients: Towards Drug Expenses Saving Regimens
作者：Zhiyuan Tan, Dirk Jan A. R. Moes* (Leiden University Medical Center, The Netherlands)
5.药物基因组检测或治疗药物监测：定量框架
Pharmacogenetic Testing or Therapeutic Drug Monitoring: A Quantitative Framework
作者：Maddalena Centanni, Lena E. Friberg* (Uppsala University, Sweden)
6.生理药代动力学模型在评估年龄和肥胖对儿童人群中左乙拉西坦处置影响的应用
Application of Physiologically Based Pharmacokinetic Modeling to Characterize the Effects of Age and Obesity on the Disposition of Levetiracetam in the Pediatric Population
作者：Patricia D. Maglalang, Daniel Gonzalez* (The University of North Carolina at Chapel Hill, USA; Duke University School of Medicine, USA)
7.P2X3受体拮抗剂Eliapixant在I期临床试验中的安全性和中国健康参与者与日本参与者的药代动力学比较
P2X3 Receptor Antagonist Eliapixant in Phase I Clinical Trials: Safety and Inter-ethnic Comparison of Pharmacokinetics in Healthy Chinese and Japanese Participants
作者：Xuening Li, Pei Liu* (Zhongshan Hospital, Fudan University, China; Bayer Healthcare Co. Ltd., China)